Mazza Mario Gennaro, Rossetti Aurora, Botti Eugenia Rossana, Clerici Massimo
Department of Medicine and Surgery, University of Milano Bicocca, Monza Psychiatric Inpatients Unit, Hospital of Desio, ASST of Monza, Italy.
Medicine (Baltimore). 2018 Jun;97(25):e10788. doi: 10.1097/MD.0000000000010788.
Vortioxetine is a new multimodal antidepressant approved by the Food and Drug Administration for the treatment of Major Depressive Disorder and recently introduced in Europe. While antidepressant properties of vortioxetine and its tolerability have been demonstrated by preclinical and clinical studies data on the safety of vortioxetine after overdose are still lacking.
A 50-year-old Caucasian man presenting a severe depressive episode that in a suicide attempt he took vortioxetine at 250 mg.
Suicide attempt by vortioxetine in a patient affected by Major Depressive Disorder.
General evaluations and gastric lavage with 2 L of water plus 50 g of activated charcoal was performed. After 12 hours of clinical stability, the patient was discharged from the emergency department and considering the suicidal ideation he was admitted to the inpatients psychiatric department.
After vortioxetine overdose the patient displayed no clinical signs or symptoms resulting from the exposure suggesting a good safety in overdose.
Overdose safety of different antidepressant drugs is a matter of great considering that overdose in individuals affected by Major Depressive Disorder frequently involves prescribed antidepressants. Previous studies showed wide variation in the relative toxicity of different antidepressant drugs with higher toxicity for tricyclic antidepressants, followed by venlafaxine bupropion and mirtazapine and lower for selective serotonin reuptake inhibitors. By now there is limited clinical trial experience regarding human overdose with vortioxetine and the maximum single dose tested was 75 mg in men associated with increased rates of nausea, dizziness, diarrhea, abdominal discomfort, generalized pruritus, somnolence, and flushing. Even if there is still limited available evidence and further investigation is needed to better understand the potential risk of vortioxetine overdose; from our case, it seems that vortioxetine overdose at 250 mg (12 times the common daily dose) showed no signs or symptoms resulting from the exposure suggesting a good safety in overdose.
伏硫西汀是一种新型多模式抗抑郁药,已获美国食品药品监督管理局批准用于治疗重度抑郁症,最近在欧洲上市。虽然临床前和临床研究已证实伏硫西汀的抗抑郁特性及其耐受性,但仍缺乏关于过量服用伏硫西汀后安全性的数据。
一名50岁的白人男性出现严重抑郁发作,在自杀未遂时服用了250毫克伏硫西汀。
重度抑郁症患者服用伏硫西汀自杀未遂。
进行了常规评估,并给予2升水加50克活性炭洗胃。经过12小时的临床稳定后,患者从急诊科出院,鉴于其自杀意念,被收治入精神科住院部。
过量服用伏硫西汀后,患者未出现因接触该药物导致的临床体征或症状,提示过量服用时安全性良好。
鉴于重度抑郁症患者过量服药时经常涉及处方抗抑郁药,不同抗抑郁药的过量服用安全性是一个非常重要的问题。先前的研究表明,不同抗抑郁药的相对毒性差异很大,三环类抗抑郁药毒性较高,其次是文拉法辛、安非他酮和米氮平,选择性5-羟色胺再摄取抑制剂毒性较低。目前关于伏硫西汀过量服用的人体临床试验经验有限,测试的最大单剂量在男性中为75毫克,会增加恶心、头晕、腹泻、腹部不适、全身瘙痒、嗜睡和脸红的发生率。即使现有证据仍然有限,需要进一步研究以更好地了解伏硫西汀过量服用的潜在风险;从我们的病例来看,250毫克(常用日剂量的12倍)伏硫西汀过量服用未出现因接触该药物导致的体征或症状,提示过量服用时安全性良好。